$KTTA

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

MIAMI, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. KTTA ( "Pasithea" or the "Company" ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management's live presentation at the ...

Original reporting
Benzinga · Globe Newswire
Published Aug 29, 2025, 12:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2025, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW) — source image
Decision brief

The 30-second read

$KTTANeutralMed
01

Why it matters

The scheduled presentation could enhance investor awareness and interest, potentially influencing stock price in the short term.

02

Market read

The event is relevant to biotech investors and could lead to increased trading activity in KTTA, especially if the presentation yields positive outlooks.

03

What to watch

Broader market conditions and upcoming biotech sector developments could overshadow this event's influence.

Timing: Immediate, as the event is scheduled soon and may cause short-term volatility.

Background

Pasithea Therapeutics is developing innovative treatments, including PAS-004, a macrocyclic MEK inhibitor, with upcoming investor events aimed at raising visibility.

Company-level read

Ticker impact

$KTTANeutralMedium confidence
Context

The news pertains to Pasithea Therapeutics' scheduled presentation at an upcoming investment conference, which is relevant to investors and traders monitoring biotech and pharmaceutical sectors.

Expected impact

Moderate upward price movement expected in the short term, contingent on investor reception.

Evidence & confidence

The event's timing and visibility could influence investor sentiment positively, but the actual impact depends on broader market conditions and investor reactions.

$KTTAWNeutralLow confidence
Context

KTTAW is a warrant linked to Pasithea Therapeutics' stock, with minimal direct impact unless KTTA experiences significant movement.

Expected impact

Negligible impact expected.

Evidence & confidence

The warrant's value is primarily driven by the underlying stock's performance; limited direct influence from the conference update.

Market effects

Potential increased interest in biotech sector stocks ahead of upcoming conferences.

Limited regional impact; primarily affecting US-based biotech stocks.

Minimal global impact; sector-specific event.

Counterpoint

The conference update may be a routine scheduling change with minimal market impact, and any price movement could be short-lived.

Key entities

  • Pasithea Therapeutics

    A clinical-stage biotechnology company developing novel therapeutics.

  • PAS-004

    A next-generation macrocyclic MEK inhibitor in development.

Related articles

$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.